<rdf:RDF xmlns:rdf="http://www.openarchives.org/OAI/2.0/rdf/" xmlns:ow="http://www.ontoweb.org/ontology/1#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:ds="http://dspace.org/ds/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/rdf/ http://www.openarchives.org/OAI/2.0/rdf.xsd">
   <ow:Publication rdf:about="oai:digibug.ugr.es:10481/92089">
      <dc:title>Effectiveness of two probiotics in the prevention of necrotizing enterocolitis in a cohort of very-low-birth-weight premature newborns</dc:title>
      <dc:creator>Uberos Fernández, José</dc:creator>
      <dc:creator>Campos Martínez, Ana María</dc:creator>
      <dc:creator>Fernández-Marín, Elizabeth</dc:creator>
      <dc:creator>Blanca Jóver, Enrique</dc:creator>
      <dc:creator>Cubero Millán, Isabel</dc:creator>
      <dc:creator>Ruiz-López, Aida</dc:creator>
      <dc:subject>Infant</dc:subject>
      <dc:subject>Premature</dc:subject>
      <dc:subject>Probiotics</dc:subject>
      <dc:subject>Necrotizing enterocholitis</dc:subject>
      <dc:subject>Morbidity</dc:subject>
      <dc:description>Some studies have reported a decreased incidence of enterocolitis necrotizing after supplementation with probiotics. However, few studies have considered the equivalence or otherwise of different strains in preventing enterocolitis necrotizing in newborns. A prospective observational study was conducted in a cohort of 291 VLBW newborns, designed to assess the prevalence of enterocolitis necrotizing after receiving supplementation with the probiotic Inforan® (Berna Biotech, Madrid, Spain) 250 mg capsules containing 109 colony forming units (CFU) Lactobacillus acidophilus (ATCC 4356) and 109 CFU Lactobacillus. bifidum (ATCC 15696) (European Medicines Agency, 2014); Bivos® (Ferring, Madrid, Spain) containing Lacticaseibacillus rhamnosus (LGG) (ATCC 53103) (109 CFU); or no probiotic. Statistical analysis was performed using multivariant regression with days of parenteral nutrition, NICU stay, oxygenotherapy and chorioamnionitis. 173 VLBW newborns received probiotic supplementation, 65 received Infloran® and 108 Bivos®. In 72 VLBW newborns no probiotic was administered. We observed a significant association between reduction of necrotizing enterocolitis ≥ grade 2 and probiotic use. For Infloran® OR 0.174 (CI 95% 0.032, 0.936), for Bivos® OR 0.196 (CI95% 0.053, 0.732). Although both probiotics are associated with a lower prevalence of necrotizing enterocolitis in VLBW newborns, the comparison between Infloran® or Bivos® does not show significant differences.</dc:description>
      <dc:date>2024-05-27T07:25:43Z</dc:date>
      <dc:date>2024-05-27T07:25:43Z</dc:date>
      <dc:date>2022-02-28</dc:date>
      <dc:type>info:eu-repo/semantics/article</dc:type>
      <dc:identifier>Published version: Uberos J, Campos-Martinez A, Fernandez-Marín E, Millan IC, Lopez AR, Blanca-Jover E. Effectiveness of two probiotics in preventing necrotising enterocolitis in a cohort of very-low-birth-weight premature new-borns. Benef Microbes. 2022 Feb 28;13(1):25-31. doi: 10.3920/BM2021.0088</dc:identifier>
      <dc:identifier>https://hdl.handle.net/10481/92089</dc:identifier>
      <dc:identifier>10.3920/BM2021.0088</dc:identifier>
      <dc:language>eng</dc:language>
      <dc:rights>http://creativecommons.org/licenses/by-nc-nd/3.0/</dc:rights>
      <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
      <dc:rights>Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License</dc:rights>
      <dc:publisher>Brill</dc:publisher>
   </ow:Publication>
</rdf:RDF>